David Choi, PharmD Profile
David Choi, PharmD

@IBDPharmD

Followers
394
Following
455
Media
31
Statuses
195

Clinical Pharmacy Specialist - Inflammatory Bowel Disease University of Chicago Medicine

Joined August 2021
Don't wanna be here? Send us removal request.
@IBDPharmD
David Choi, PharmD
2 years
The current prior authorization process leads to unnecessary delays that is detrimental to patient care! We need prior authorization reform now! @IBDMD @DocCohenIBD @UChicagoIBD @UChicagoGI @CrohnsColitisFn #IBD
2
14
50
@IBDPharmD
David Choi, PharmD
5 days
With ease of starting IL23 for IBD (good insurance coverage, bridge program). Should we stop trying to dose escalate Stelara? There are substantial delays with appeals process (months) and extra work needed to appeal! #GITwitter #IBD.
1
0
2
@IBDPharmD
David Choi, PharmD
28 days
0
0
1
@IBDPharmD
David Choi, PharmD
28 days
Just kicked off our 3rd Annual IBD pharmacist symposium with @IBDProNews! We had a record 197 patients enroll with this symposium!! #IBD #gitwitter
Tweet media one
2
3
23
@IBDPharmD
David Choi, PharmD
1 month
RT @EdwardLoftus2: ACG Clinical Guideline: Management of Crohn's Disease in. : Official journal of the American College of Gastroenterolo….
0
36
0
@IBDPharmD
David Choi, PharmD
1 month
RT @IBDPharmD: We are excited to be planning our third IBD Pharmacist Virtual Symposium for June 07, 2025! We are hoping to introduce Innov….
0
5
0
@IBDPharmD
David Choi, PharmD
1 month
We have observed significantly higher rates (almost 30%) of acne with upadacitinib (JAKne) than in clinic trials (~7-8%). We found younger age, upadacitinib dose and female gender being risk factors for development! @amelia_kellar @IBDMD @Klein_Jeremy.
@amelia_kellar
Amelia Kellar
1 month
Grateful to be a part of this important work led by @IBDPharmD @IBDMD examining incidence and risk factors for development of acne in IBD patients treated with upadacitinib @Klein_Jeremy @UChicagoIBD.
1
7
32
@IBDPharmD
David Choi, PharmD
2 months
One of the biggest challenges we have been encountering for #IBD care are the increasing role of quantity limit PAs! Although we are getting medications approved they are requiring a separate PA for the dose. These are leading to significant delays in care! #GITwitter.
0
2
8
@IBDPharmD
David Choi, PharmD
4 months
Tremfya is FDA approved for Crohn's disease! This has both IV (200 mg) and subq (400 mg) induction loading dose options followed by subq maintenance dose (100 mg or 200 mg). #GITwitter #IBD .
1
12
40
@IBDPharmD
David Choi, PharmD
4 months
We are excited to be planning our third IBD Pharmacist Virtual Symposium for June 07, 2025! We are hoping to introduce Innovation Presentations that showcases amazing innovations by IBD pharmacy teams across the country! #GI #IBD #GITwitter.
@IBDProNews
Crohn’s & Colitis Foundation IBD Pro
4 months
🚨 Calling all #IBD #pharmacists! 🚨 Have an innovation that’s advancing IBD care? Submit your work for the IBD Pharmacist Virtual Symposium on June 7, 2025. 📝 Submission window: March 10 – April 4, 2025 .⏳ 15-minute presentations .Apply now! ➡️
0
5
19
@IBDPharmD
David Choi, PharmD
5 months
EDIT: Delays in therapy if a dedicated pharmacy team is NOT involved.
1
1
4
@IBDPharmD
David Choi, PharmD
5 months
IBD PharmDs can be an important member of the care team! This study shows delays in therapy if a PharmD is involved 🤔. The value an IBD PharmD brings ensures safe, effective, and timely initiation and continuation of therapies! #IBD #PharmD #GITwitter.
3
4
25
@IBDPharmD
David Choi, PharmD
6 months
Omvoh is now FDA approved for Crohn's disease! ##GITWITTER #IBD
1
2
4
@IBDPharmD
David Choi, PharmD
6 months
RT @IBDAPN: 🚨 Today is the day! . Register here so you do not miss out on this incredible ChatAPP IBD Case Series by APPs for APPs! . https….
0
1
0
@IBDPharmD
David Choi, PharmD
6 months
RT @ibdtweets: Clinical pharmacists should ideally be part of a multidisciplinary team to improve holistic care of IBD patients. 🌸 Clinical….
0
7
0
@IBDPharmD
David Choi, PharmD
6 months
Please join us for this important discussion!! We will be discussing how to successfully start and keep patients on therapy and how to transition from IV to SQ successfully! #GITwitter #IBD.
@IBDAPN
Marita Kametas
6 months
Join us on January 14th at 6pm CST to participate in a dynamic discussion between @IBDAPN , @AngelinaIBDNP , #KimberlyOrleck & @IBDPharmD about sequencing, management and access to IL-23 therapies.
0
1
3
@IBDPharmD
David Choi, PharmD
6 months
RT @IBDAPN: Join us on January 14th at 6pm CST to participate in a dynamic discussion between @IBDAPN , @AngelinaIBDNP , #KimberlyOrleck &….
0
1
0
@IBDPharmD
David Choi, PharmD
7 months
The 7th Stelara biosimilar has been FDA approved! Ustekinumab-stba (Steqeyma; Celltrion) is expected to launch 02/2025! 🎉 #Biosimilar #IBD #GITwitter. -45 mg/0.5 mL or 90 mg/1 mL prefilled syringe.-130 mg/26 mL intravenous infusion.
0
2
6
@IBDPharmD
David Choi, PharmD
7 months
RT @GI_PharmD: 1️⃣st ever pharmacy track at #AIBD2024 ✅.Thanks to @MRegueiroMD @DrCoreySiegel @MLongMD @NMH_SHanauerMD @IBDConference for r….
0
11
0
@IBDPharmD
David Choi, PharmD
7 months
What an amazing turnout to the first IBD Pharmacist Track at AIBD. @GI_PharmD and I are so grateful for the opportunity to have this session!! Thank you to AIBD for making this happens! #AIBD2024
Tweet media one
4
6
38
@IBDPharmD
David Choi, PharmD
7 months
Such a great presentation by @MRegueiroMD about managememt of complications with Crohn's Disease! I always learn so much! #AIBD2024
Tweet media one
0
4
19